These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15279126)

  • 1. Counseling buprenorphine patients: information and treatment approaches for counselors.
    McCann MJ
    J Psychoactive Drugs; 2004 May; Suppl 2():139-46. PubMed ID: 15279126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.
    Strain EC; Stoller K; Walsh SL; Bigelow GE
    Psychopharmacology (Berl); 2000 Mar; 148(4):374-83. PubMed ID: 10928310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
    Resnick RB
    Ann Intern Med; 2003 Feb; 138(4):360. PubMed ID: 12585846
    [No Abstract]   [Full Text] [Related]  

  • 6. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
    Weiss RD; Griffin ML; Potter JS; Dodd DR; Dreifuss JA; Connery HS; Carroll KM
    Drug Alcohol Depend; 2014 Jul; 140():118-22. PubMed ID: 24831754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New pharmacological tool approved for opioid addiction.
    Sansovich D
    HIV Clin; 2004; 16(3):9-11. PubMed ID: 15366107
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine diffusion: the attitudes of substance abuse treatment counselors.
    Knudsen HK; Ducharme LJ; Roman PM; Link T
    J Subst Abuse Treat; 2005 Sep; 29(2):95-106. PubMed ID: 16135338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Narrative review: buprenorphine for opioid-dependent patients in office practice.
    Sullivan LE; Fiellin DA
    Ann Intern Med; 2008 May; 148(9):662-70. PubMed ID: 18458279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
    Stock C; Shum JH
    J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid dependence treatment, including buprenorphine/naloxone.
    Raisch DW; Fye CL; Boardman KD; Sather MR
    Ann Pharmacother; 2002 Feb; 36(2):312-21. PubMed ID: 11847954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.
    Clay E; Khemiri A; Zah V; Aballéa S; Ruby J; Asche CV
    J Med Econ; 2014 Sep; 17(9):626-36. PubMed ID: 24841329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.
    Fudala PJ; Yu E; Macfadden W; Boardman C; Chiang CN
    Drug Alcohol Depend; 1998 Mar; 50(1):1-8. PubMed ID: 9589267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved?
    Caldiero RM; Parran TV; Adelman CL; Piche B
    Am J Addict; 2006; 15(1):1-7. PubMed ID: 16449087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine maintenance: a new treatment for opioid dependence.
    Collins GB; McAllister MS
    Cleve Clin J Med; 2007 Jul; 74(7):514-20. PubMed ID: 17682629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.